Advertisement
U.S. markets closed

SenesTech, Inc. (SNES)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8910-0.0085 (-0.94%)
At close: 04:00PM EST
0.8645 -0.03 (-2.97%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8995
Open0.9100
Bid0.8900 x 1800
Ask0.9700 x 900
Day's Range0.8600 - 0.9100
52 Week Range0.5200 - 29.0400
Volume123,709
Avg. Volume2,311,525
Market Cap4.584M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-61.3200
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SNES

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SenesTech, Inc.
    Analyst Report: ICON Public Limited CompanyIcon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Insider Monkey

    SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Call Transcript

    SenesTech, Inc. (NASDAQ:SNES) Q4 2023 Earnings Call Transcript February 23, 2024 SenesTech, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the SenesTech Reports Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. [Operator […]

  • Simply Wall St.

    SenesTech Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

    SenesTech ( NASDAQ:SNES ) Full Year 2023 Results Key Financial Results Revenue: US$1.19m (up 17% from FY 2022). Net...

  • PR Newswire

    SenesTech Announces 2023 Financial Results

    SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2023 financial results.